Literature DB >> 17504799

Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis.

E Gamble1, D C Grootendorst, K Hattotuwa, T O'Shaughnessy, F S F Ram, Y Qiu, J Zhu, A M Vignola, C Kroegel, F Morell, I D Pavord, K F Rabe, P K Jeffery, N C Barnes.   

Abstract

Bronchial biopsy specimens from chronic obstructive pulmonary disease (COPD) patients demonstrate increased numbers of CD8+ T-lymphocytes, macrophages and, in some studies, neutrophils and eosinophils. Smoking cessation affects the rate of forced expiratory volume in one second (FEV(1)) decline in COPD, but the effect on inflammation is uncertain. Bronchial biopsy inflammatory cell counts were compared in current and ex-smokers with COPD. A pooled analysis of subepithelial inflammatory cell count data from three bronchial biopsy studies that included COPD patients who were either current or ex-smokers was performed. Cell count data from 101 subjects, 65 current smokers and 36 ex-smokers, were analysed for the following cell types: CD4+ and CD8+ T-lymphocytes, CD68+ (monocytes/macrophages), neutrophil elastase+ (neutrophils), EG2+ (eosinophils), mast cell tryptase+ and cells mRNA-positive for tumour necrosis factor-alpha. Current smokers and ex-smokers were similar in terms of lung function, as measured by FEV(1) (% predicted), forced vital capacity (FVC) and FEV(1)/FVC. The results demonstrate that there were no significant differences between smokers and ex-smokers in the numbers of any of the inflammatory cell types or markers analysed. It is concluded that, in established chronic obstructive pulmonary disease, the bronchial mucosal inflammatory cell infiltrate is similar in ex-smokers and those that continue to smoke.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17504799     DOI: 10.1183/09031936.00013006

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  53 in total

1.  Bronchial secretory immunoglobulin a deficiency correlates with airway inflammation and progression of chronic obstructive pulmonary disease.

Authors:  Vasiliy V Polosukhin; Justin M Cates; William E Lawson; Rinat Zaynagetdinov; Aaron P Milstone; Pierre P Massion; Sebahat Ocak; Lorraine B Ware; Jae Woo Lee; Russell P Bowler; Alexey V Kononov; Scott H Randell; Timothy S Blackwell
Journal:  Am J Respir Crit Care Med       Date:  2011-04-21       Impact factor: 21.405

2.  A novel technique to explore the functions of bronchial mucosal T cells in chronic obstructive pulmonary disease: application to cytotoxicity and cytokine immunoreactivity.

Authors:  M W Lethbridge; D M Kemeny; J C Ratoff; B J O'Connor; C M Hawrylowicz; C J Corrigan
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

3.  Inhibitors of ceramide de novo biosynthesis rescue damages induced by cigarette smoke in airways epithelia.

Authors:  Aida Zulueta; Anna Caretti; Giuseppe Matteo Campisi; Andrea Brizzolari; Jose Luis Abad; Rita Paroni; Paola Signorelli; Riccardo Ghidoni
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-04-13       Impact factor: 3.000

Review 4.  COPD: what is the unmet need?

Authors:  P M A Calverley
Journal:  Br J Pharmacol       Date:  2008-09-15       Impact factor: 8.739

5.  Airway epithelial cell PPARγ modulates cigarette smoke-induced chemokine expression and emphysema susceptibility in mice.

Authors:  Siva Kumar Solleti; Dawn M Simon; Sorachai Srisuma; Meltem C Arikan; Soumyaroop Bhattacharya; Tirumalai Rangasamy; Kaiser M Bijli; Arshad Rahman; Joseph T Crossno; Steven D Shapiro; Thomas J Mariani
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-05-29       Impact factor: 5.464

6.  Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD.

Authors:  Elizabeth Sapey; Ali Ahmad; Darren Bayley; Paul Newbold; Noel Snell; Paul Rugman; Robert A Stockley
Journal:  J Clin Immunol       Date:  2009-03-17       Impact factor: 8.317

7.  Lymphoid follicle cells in chronic obstructive pulmonary disease overexpress the chemokine receptor CXCR3.

Authors:  Steven G Kelsen; Mark O Aksoy; Mary Georgy; Richard Hershman; Rong Ji; Xiuxia Li; Matthew Hurford; Charalambos Solomides; Wissam Chatila; Victor Kim
Journal:  Am J Respir Crit Care Med       Date:  2009-02-12       Impact factor: 21.405

Review 8.  Influencing the decline of lung function in COPD: use of pharmacotherapy.

Authors:  Ekaterina S Gladysheva; Atul Malhotra; Robert L Owens
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-06-03

9.  Smoking status and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients.

Authors:  Suzana E Tanni; Nilva Rg Pelegrino; Aparecida Yo Angeleli; Camila Correa; Irma Godoy
Journal:  J Inflamm (Lond)       Date:  2010-06-09       Impact factor: 4.981

10.  Enhanced effector function of cytotoxic cells in the induced sputum of COPD patients.

Authors:  Richard A Urbanowicz; Jonathan R Lamb; Ian Todd; Jonathan M Corne; Lucy C Fairclough
Journal:  Respir Res       Date:  2010-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.